Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Osteoporosis
•
Bisphosphonate
Do you use bisphosphonates in combination with SERMs in female patients with progressive decline in bone density despite being on a SERM for post-menopausal symptoms other than osteoporosis?
Related Questions
For postmenopausal osteoporosis, would you give denosumab after a course of teriparatide and romosozumab to women who had an atypical femoral fracture while on bisphosphonate therapy a few years earlier?
Is there any contraindication for use of Invisalign teeth aligners in patients undergoing treatment for osteoporosis?
Would you have concerns with continuing denosumab for much longer than the available ten year clinical safety trial data for an individual with renal insufficiency with persistent osteoporosis/history of compression fractures?
How do you manage hepatotoxicity thought to be related to Romosozumab use?
Would you consider PTH-analog therapy in a woman with osteoporotic vertebral fractures who has asymptomatic non-obstructive renal stones and normal 24-hour urine calcium level?
Do you routinely use anti-resorptive medications in patients who have osteoporosis and longstanding hypoparathyroidism?
What is your approach to management of methotrexate osteopathy?
During treatment of severe osteoporosis, with PTH analogs (abaloparatide or) would rise in alkaline phosphatase level > 200 (in setting of normal GGT) warrant discontinuation of medication?
Would you continue zolendronic acid infusions if the bone density decreases significantly in year two?
How would you approach a finding of osteoporosis (Z score -4.5) in a recently postpartum patient who had DEXA sent for long-term low-dose glucocorticoid use?